Eloralintide plus tirzepatide drives 23.3% weight loss in phase 2 diabetes trial

The wire

1. 01Lilly's once-weekly amylin receptor agonist eloralintide at 9 mg with tirzepatide 15 mg produced 23.3% weight loss at 48 weeks in adults with type 2 diabetes and overweight or obesity, versus 3% with placebo.
2. 02Combination arms at 6 mg plus tirzepatide 10 mg and 5 mg reached 19.9% and 19.4%, offering clinicians a possible route to pair glucose and weight targets in diabetes.
3. 03This is phase 2 data presented at a conference with 367 participants across 10 arms; safety detail and longer-term durability were not reported in this account.

From the source

Combining amylin agonist with tirzepatide leads to further weight loss in type 2 diabetes

An investigational amylin receptor agonist combined with tirzepatide induced weight loss of up to 23.3% for adults with type 2 diabetes and obesity, according to data from a phase 2 2 trial.